Stephan Grupp, MD, PhD, and Beverly Davidson, PhD Two renowned experts from Children’s Hospital of Philadelphia (CHOP) have been elected to the National Academy of Medicine (NAM), effective October 1, 2019. Election to the NAM is considered one of the highest honors in the fields of health and medicine.
“CHOP has the brightest minds in cellular and gene therapy under one roof, coupled with unparalleled experience with the first-to-market approved gene therapies, and our unique infrastructure makes it possible to deliver these therapies, said Bryan Wolf, MD, PhD, Executive Vice President, Children’s Hospital of Philadelphia, and Chief Scientific Officer at the Children’s Hospital of Philadelphia Research Institute. “All of this powers our pediatric research hospital to aggressively pursue and lead treatment breakthroughs. Dr. Davidson’s and Dr. Grupp’s elections to the National Academy of Medicine are very well deserved.”
Davidson was recognized for being on the forefront of developing innovative therapies and medicines for fatal, inherited brain disorders, which are engineered to either remove toxic proteins or replace missing proteins, and for improving or preventing disease progression.
Grupp was recognized for pioneering the development of an entirely novel therapy for acute lymphoblastic leukemia (ALL), and leading the first global engineered cell therapy trial that demonstrated effective sustained ALL remissions, making him a leader in cancer immunotherapy.